Australia markets closed

Fortress Biotech, Inc. (CNB.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.8962+0.0024 (+0.27%)
At close: 08:03AM CEST
Full screen
Previous close0.8938
Open0.8962
Bid0.7970 x 500000
Ask0.8212 x 500000
Day's range0.8962 - 0.8962
52-week range0.7264 - 3.8000
Volume4,099
Avg. volume73
Market cap99.541M
Beta (5Y monthly)1.99
PE ratio (TTM)N/A
EPS (TTM)-0.8190
Earnings date14 Nov 2022 - 18 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est10.17
  • GlobeNewswire

    Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences

    WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in two upcoming investor conferences. Details are as follows: Cantor Fitzgerald’s Oncology, Hematology & HemeOnc Conference:Date: Wednesday, September 28, 2022Time: 1:45 PM ETFormat: Panel Discussion & 1x1 meetingsPanel: Trends and C

  • GlobeNewswire

    Fortress Biotech to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

    MIAMI, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress” or “the Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman and Chief Executive Officer, will present a corporate update virtually at the H.C. Wainwright 24th Annual Global Investment Conference and the Company will p

  • GlobeNewswire

    Mustang Bio to Participate in Upcoming September 2022 Investor Conferences

    WORCESTER, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in New York City. Details of the events are as follows: